Pacific Biosciences of California

PACB · NASDAQ

$1.96+$0.12 (+6.52%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $1.84

PACB analyst rating

HoldConsensus of 4 analysts over the last 12 months. 25% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform1
Sell0

12-month price target · 9 analysts

Average $2.20 (+12.3% upside)

Low: $1.26
Now: $1.96
High: $3.15

Upgrades and downgrades

The latest rating actions, newest first

PACB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Sep 9, 2026	Initiates	Neutral	$1.50 → $1.35	59%
Barclays	May 11, 2026	Maintains	Underweight	$1.00 → $1.50	54%
Barclays	Apr 14, 2026	Maintains	Underweight	$1.50 → $1.00	54%
Barclays	Mar 6, 2026	Downgrade	Equal-Weight → Underweight	$2.00 → $1.50	54%
Barclays	Dec 15, 2025	Maintains	Equal-Weight	$1.50 → $2.00	54%
Piper Sandler	Nov 11, 2025	Maintains	Neutral	$1.50 → $2.00	58%
Stephens & Co.	Nov 10, 2025	Maintains	Overweight	$1.80 → $2.00	51%

The case for and against

Updated Oct 31, 2025

Bull case

Pacific Biosciences of California Inc has demonstrated a positive financial trajectory, evidenced by an improved gross margin year-over-year, largely driven by a greater proportion of consumables revenue. The company has reported increased utilization of its Revio sequencing platform, reaching its highest levels since launch, which suggests robust demand for its products. Additionally, management anticipates sequential growth in Vega placements throughout the year, indicating a strong outlook for large-scale projects and overall business expansion.

Bear case

Pacific Biosciences of California Inc is facing a negative outlook due to an anticipated decline in gross margins, projected to fall below the 40.4% reported in the previous quarter. Additionally, there are concerns regarding stagnant utilization rates and weaker than expected demand for new instruments, potentially jeopardizing the company's financial targets for 2026. Furthermore, ongoing demand weakness in the critical market of China is expected to continue throughout 2023 and into 2024, further impacting the company's performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.